Actively Recruiting
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Led by Beijing Tiantan Hospital · Updated on 2025-02-17
366
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium
CONDITIONS
Official Title
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with temporal glioma scheduled for a elective craniotomy
- Age 6518 years
- Obtain written informed consent.
You will not qualify if you...
- Patients with severe preoperative cognitive impairment
- History of traumatic brain injury or previous neurosurgery
- History of psychotropic medications
- Allergy to dexmedetomidine
- Pregnant or lactating women
- History of obstructive sleep apnoea syndrome
- Severe bradycardia (heart rate <40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
- Severe hepatic dysfunction
- Severe renal dysfunction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, China
Actively Recruiting
Research Team
Y
Yuming Peng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here